Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Prednisone Maintenance Post-ASCT in Multiple Myeloma
NCT00006890Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jul 2000
- Primary completion
- May 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Incidence of drop-out or dose reduction at 2 years. Started Jul 2000; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00006890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006890.